Minority Pediatric Patients with Inflammatory Bowel Disease Demonstrate an Increased Length of Stay

被引:20
|
作者
Barnes, Edward L. [1 ]
Kochar, Bharati [1 ]
Long, Millie D. [1 ,2 ]
Martin, Christopher F. [1 ,2 ]
Kappelman, Michael D. [2 ,3 ]
机构
[1] Univ North Carolina Chapel Hill, Div Gastroenterol & Hepatol, 130 Mason Farm Rd,Bioinformat Bldg,CB 7080, Chapel Hill, NC 27599 USA
[2] Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Div Pediat Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
race; length of stay; pediatric inflammatory bowel disease; SERIOUS BACTERIAL-INFECTIONS; FACTOR-ALPHA ANTAGONISTS; NON-HISPANIC WHITES; UNITED-STATES; ULCERATIVE-COLITIS; CROHNS-DISEASE; AFRICAN-AMERICANS; RETROSPECTIVE COHORT; RACIAL DISPARITIES; COLECTOMY RATES;
D O I
10.1097/MIB.0000000000001267
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Genetic and other biological factors may lead to differences in disease behavior among children with inflammatory bowel disease of different races, which may be further modified by disparities in care delivery. Using the Kids' Inpatient Database, we aimed to evaluate differences in the management of pediatric patients with inflammatory bowel disease by race, focusing on length of stay (LOS). Methods: We performed a cross-sectional analysis using 2000 to 2012 data from the Kids' Inpatient Database, a nationally representative database. We identified pediatric patients (<= 18 years of age) with discharge diagnoses of Crohn's disease (CD) or ulcerative colitis (UC). We used multivariable logistic regression to evaluate the relationship between race and LOS, controlling for age, payer status need for surgery, and year of admission. Results: We identified 27,295 hospitalizations for children with inflammatory bowel disease (62% CD and 38% UC), Compared with white patients with CD, black (adjusted odds ratio 1.37; 95% confidence interval, 1.22-1.53; P < 0.001) and Hispanic patients (adjusted odds ratio: 1.37; 95% confidence interval: 1.19-1.59; P < 0.001) with CD demonstrated increased odds of a LOS greater than the 75th percentile. When compared with white patients with UC, Hispanic patients also demonstrated increased odds of a LOS greater than the 75th percentile (adjusted odds ratio: 1.20; 95% confidence interval, 1.02-1.42, P = 0.015). Conclusions: After controlling for age, year of admission, and clinical phenotypes, black and Hispanic patients with CD and Hispanic patients with UC had longer LOS than white patients. These may be due to differences in provider/hospital characteristics, socioeconomic differences, and/or differences in genetics and other biological factors.
引用
收藏
页码:2189 / 2196
页数:8
相关论文
共 50 条
  • [41] Disaccharidase Deficiency in Pediatric Patients with Inflammatory Bowel Disease
    Friesen, Chance S.
    San Pablo, William
    Bass, Julie
    Garg, Uttam
    Colombo, Jennifer M.
    GASTROINTESTINAL DISORDERS, 2022, 4 (01): : 1 - 7
  • [42] Vedolizumab Use in Pediatric Patients With Inflammatory Bowel Disease
    Singh, Namita
    Patel, Minesh
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2015, 148 (04) : S72 - S72
  • [43] Use of rifaximin in pediatric patients with inflammatory bowel disease
    Muniyappa, Pramodha
    Gulati, Reema
    Vera, Hupertz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S551 - S551
  • [44] Intestinal Transplantation for Inflammatory Bowel Disease: Trends in Cases, Length of Stay, and Survival Odds
    Mensah, Boniface
    Gaddipati, Greeshma N.
    Vasireddy, Ramya
    Atarere, Joseph
    Bilalaga, Mariah Malak
    Singh, Simardeep
    Kanth, Priyanka
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S807 - S808
  • [45] Dermatologic manifestations in pediatric patients with inflammatory bowel disease
    Afarideh, Mohsen
    Bartoletta, Katherine
    Tollefson, Megha M.
    PEDIATRIC DERMATOLOGY, 2024, 41 (02) : 234 - 242
  • [46] Use of infliximab in pediatric patients with inflammatory bowel disease
    Serrano, MS
    Schmidt-Sommerfeld, E
    Kilbaugh, TJ
    Brown, RF
    Udall, JN
    Mannick, EE
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 823 - 828
  • [47] Methotrexate therapy for pediatric patients with inflammatory bowel disease
    Kirschner, BS
    INFLAMMATORY BOWEL DISEASES, 1998, 4 (02) : 121 - 123
  • [48] Mycobiome signature in pediatric patients with Inflammatory Bowel Disease
    Murugesan, S.
    Kumar, M.
    Saadaoui, M.
    Elhag, D. A.
    Hendaus, M. A.
    Ibrahim, N.
    Al-Mudhaka, F.
    AbuHazima, K.
    Akobeng, A.
    Elawad, M.
    Al Khodor, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 462 - 462
  • [49] Exercise Capacity in Pediatric Patients with Inflammatory Bowel Disease
    Ploeger, Hilde E.
    Takken, Tim
    Wilk, Boguslaw
    Issenman, Robert M.
    Sears, Ryan
    Suri, Soni
    Timmons, Brian W.
    JOURNAL OF PEDIATRICS, 2011, 158 (05): : 814 - 819
  • [50] Inflammatory Bowel Disease in Pediatric Patients With Cerebral Palsy
    Colson, Steven B.
    Siparsky, Georgette L.
    Capocelli, Kelley E.
    Pan, Zhaoxing
    Sokol, Ronald J.
    Hoffenberg, Edward J.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2013, 56 (06): : E50 - E50